Developing New Small Molecular Drugs for Prostate Cancer Therapy
نویسندگان
چکیده
منابع مشابه
Developing New Small Molecular Drugs for Prostate Cancer Therapy
Most of the early prostate cancer has no obvious symptoms, but its malignancy metastasis will cause largely deaths. The treatment options for patients with prostate cancer include traditional surgery, external beam therapy, hormone therapy, small molecular drug and cryosurgery. It was considered non-traditional treatments also can be used in alternative medicines for prostate cancer therapy. Th...
متن کاملNew drugs in prostate cancer
The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other...
متن کاملChemotherapy and New Drugs in Prostate Cancer
Prostate cancer (PrC) is the fourth most common cancer (for both sexes combined) and the second most common cancer in men (accounting for 15% of all new male cancer cases), with a worldwide incidence of approximately 1,111,200, a 5-year prevalence of 3,924,000, and a mortality incidence of 307,000 for the year 2012.1 Since the 1990s, the increasing use of prostate-specific antigen (PSA) testing...
متن کاملEvaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.
OBJECTIVE To guide the optimal selection among first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in clinical practice. This review attempted to provide a thorough comparison among three first-generation EGFR-TKIs, namely icotinib, erlotinib, and gefitinib, with regard to their molecular structure, pharmacokinetic parameters, clinical data, adverse reaction...
متن کاملPreclinical Development Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy
Hepatocyte growth factor (HGF) and its receptor c-Met are associated with increased aggressiveness of tumors and poor prognostic outcome of patients with cancer. Here, we report the development and characterization of therapeutic anti-HGF (aHGF)-Nanobodies and their potential for positron emission tomographic (PET) imaging to assess HGF expression in vivo. Two aHGF-Nanobodies designated 1E2 and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cancer Therapy
سال: 2013
ISSN: 2151-1934,2151-1942
DOI: 10.4236/jct.2013.44a009